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Abstract: 
 
Postoperative peritoneal adhesions are a common complication 
after operative treatment and they cause a significant burden to 
both individual patients and the society. This review’s purpose 
was to examine the mechanisms of postoperative peritoneal 
adhesion formation and to evaluate different adhesion 
prevention products that are either already available or being 
investigated. The reference articles were searched using mainly 
Primo Central Index. 
 
Adhesions are formed when normal peritoneal healing is 
somehow impaired. The peritoneal healing is a complicated 
process and there are multiple stages that need to be completed 
for normal healing to occur. If this is somehow interrupted, it 
can lead to poor healing or adhesion formation instead of normal 
healing. It is known that adhesions can be decreased by using 
careful surgery techniques, but there are also some risk factors 
that are related to the patient. 
 
Modern adhesion prevention products can mainly be divided 
into two groups: 1) barrier products that rely on the effect of 
keeping wounded tissue surfaces mechanically apart, and 2) 
immunomodulatory products that attempt to make the healing 
process occur without adhesion formation by taking part in the 
immunological pathways. Barrier products include solid 
membranes, liquids and gels. Immunomodulatory products 
include specifically targeted pharmacological agents as well as 
multifunctional products. 
 
Various different products have been investigated, but still the 
optimal adhesion prevention product remains undiscovered. 
Barriers are widely used, but immunomodulatory products have 
shown some interestingly promising results. Whichever type of 
product is used, it should be effective, affordable, safe and easy 
to use. 
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 Tiivistelmä: 
 
Leikkauksenjälkeiset vatsaontelon kiinnikkeet ovat merkittävä ongelma sekä yksilölle että 
yhteiskunnallisesti. Leikkauksenjälkeiset kiinnikkeet ovat hyvin yleisiä ja ne voivat aiheuttaa 
esimerkiksi suolitukoksia, hedelmättömyyttä, vatsakipuja ja komplikaatioita mahdollisten 
uusintaleikkausten yhteydessä. Yhteiskunnalle kiinnikkeistä koituvat taloudelliset kustannukset 
ovat huomattavia, ja kiinnikkeiden ehkäiseminen kohtuullisen edullisella tuotteella olisi 
kustannustehokasta. 
 
Tämän opinnäytetyön tarkoituksena on tarkastella vatsaontelon leikkauksenjälkeisten kiinnikkeiden 
muodostumismekanismeja ja arvioida niiden eri ehkäisymenetelmiä, jotka joko ovat jo kliinisessä 
käytössä tai vasta tutkimusasteella. Jotkut katsauksessa mainituista tuotteista ovat osoittautuneet 
tehokkaammiksi ja turvallisemmiksi kuin toiset. Viitteinä käytetyt artikkelit on saatu hakutuloksina 
pääasiassa käyttäen Primo Central Indexiä, jonka Turun yliopisto on tarjonnut käyttöön. 
 
Kiinnikkeitä muodostuu, kun normaali vatsakalvon haavojen paraneminen estyy tavalla tai toisella. 
Vatsakalvossa sijaitsevien vaurioiden normaali paraneminen muistuttaa ihon haavojen paranemista, 
mutta niissä on myös merkittäviä eroja, kuten se, että vatsakalvossa olevat haavat ovat jatkuvassa 
kontaktissa vatsaontelonsisäisen nesteen kanssa. Tämä neste sisältää runsaasti erilaisia sytokiineja, 
kasvutekijöitä, soluja ja proteiineja. Vatsakalvon paraneminen on monimutkainen tapahtumaketju, 
jossa on mukana useita eri soluja, proteiineja ja muita osia. Siihen kuuluu useita eri 
tapahtumavaiheita ja -polkuja, joiden tulee toimia mutkattomasti, jotta vauriot paranisivat 
normaalisti. Jos jokin näistä tapahtumaketjuista jää suoriutumatta tai muuten häiriintyy, on 
seurauksena joko huonosti parantunut vatsakalvo tai kiinnikkeiden muodostuminen. 
 
Tiedetään, että leikkauksenjälkeisten kiinnikkeiden muodostumiseen vaikuttaa merkittävästi 
leikkaustekniikka, ja tähystysleikkauksien jälkeen kiinnikkeiden muodostuminen onkin 
vähäisempää kuin avoleikkausten jälkeen. Kirurgien tulisi olla tietoisia tekniikoista, jotka 
suurentavat kiinnikkeiden riskiä. Jotkut riskitekijöistä ovat potilaaseen liittyviä, ja on mahdollista, 
että tietoa niiden olemassaolosta voitaisiin tulevaisuudessa hyödyntää suunniteltaessa yksilöllistä 
kiinnikkeidenestohoitoa. 
 
Nykyaikaiset kiinnikkeenestomenetelmät voidaan jakaa karkeasti kahteen eri osa-alueeseen: 1) 
mekaaniset esteet, jotka pitävät vaurioituneet kudosrajapinnat fyysisesti erillään, ja 2) 
immunomodulatoriset tuotteet, jotka vaikuttavat paranemisprosessin osiin vähentäen turhaa 
kiinnikkeiden muodostumista. Mekaanisiin esteisiin kuuluu kiinteitä, kalvomaisia tuotteita, sekä 
nestemäisiä ja geelimuotoisia tuotteita. Immunomodulatorisiin tuotteisiin taas kuuluu erilaisia, sekä 
yksittäisiin kohdemolekyyleihin tai -proteiineihin vaikuttavia, että moniin eri immunologisten 
prosessien kohtiin vaikuttavia aineita. 
 
Kiinnikkeiden ehkäisemistä on tutkittu paljon, ja paljon erilaisia tuotteita on jo markkinoilla tai 
tutkimusasteella. Ihanteellista vaihtoehtoa kiinnikkeiden ehkäisyyn ei kuitenkaan vielä ole kehitetty 
ja tutkimusta tarvitaan edelleen. Nykypäivänä käytetään paljon mekaaniseen estevaikutukseen 
nojaavia tuotteita, mutta myös immunomodulatorisista tuotteista on lupaavia tuloksia. Joka 
tapauksessa kiinnikkeiden estoon käytettävän tuotteen tulisi olla sekä tehokas että turvallinen, ja 
lisäksi sen tulisi olla helppokäyttöinen ja kohtuullisen edullinen. 
 
 
 
 Table of contents 
 
1. Introduction 
2. Methods 
3. Peritoneum and normal peritoneal healing 
4. Inflammatory aspects contributing to normal peritoneal healing 
4.1.Inflammatory cytokines 
4.1.1. TNF-alpha 
4.1.2. IL-6 
4.1.3. TGF-beta1 
4.2.VEGF 
4.3.Plasminogen activators 
5. Patient-related risks 
6. Surgery techniques and principles 
7. Classification of adhesions 
8. Adhesion prevention products 
8.1.Barrier products 
8.1.1. Membranes 
8.1.2. Liquids 
8.1.3. Gels 
8.2.Immunomodulatory products 
8.2.1. Anti-inflammatory 
8.2.2. Fibrinolysis activating 
8.2.3. Angiogenesis preventing 
8.2.4. Collagen synthesis preventing 
9. Discussion 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
 
Postoperative adhesion formation is the most common complication after abdominal or pelvic 
surgery 1 2. Adhesions appear in up to 94% of patients after laparotomy3. Fortunately, most 
adhesions are asymptomatic, but some will, however, cause problems for a small group of patients. 
These problems include small-bowel obstruction, female infertility, pelvic and abdominal pain4, a 
risk of difficulties and complications at reoperation1, and ‘failure to thrive’ in children5. 
 
Different prevention techniques have been studied but there is a need for further research as 
postoperative adhesions remain a significant problem causing costs (in the shape of re-
hospitalization and further surgery) in addition to individual suffering. 
 
Parker et al. discovered in a cohort study in 2001 that after lower abdominal surgery up to 32.6 
percent of patients were readmitted in the subsequent ten years for a potential adhesion-related 
problem and after open lower-abdominal surgery up to 7.3 percent of readmissions were directly 
adhesion-related6. A population-based study in 2008 showed that in children under 16 years the 
overall readmission rate due to small-bowel obstruction caused by adhesions in 5 years after open 
abdominal surgery (excluding appendicectomy) was 5.3%5. Patients with prior laparotomy, who 
therefore have more intra-abdominal adhesions, also seem to have an increased risk of bowel and 
mesenteric injury after blunt abdominal trauma7. 
 
In a review article by ten Broek et al. that studied the disease burden of the most important 
complications of postoperative abdominal adhesions, the incidence of reoperations for adhesive 
small bowel obstruction was 2.4% and adhesions were found to be the most common cause of 
postoperative small bowel obstruction (56%)1 . The same review also revealed that the incidence for 
adhesive small bowel obstruction depended on the anatomical location of previous surgery, and was 
highest in paediatric (4.2%) and lower gastrointestinal tract surgery (3.2%) and lowest in abdominal 
wall surgery (0.5%), upper gastrointestinal tract surgery (1.2%) and urological surgery (1.5%). 
 
In the USA, the total cost for adhesiolysis hospitalizations was 1.44 billion dollars in 1988 and 1.33 
billion dollars in 1994. The decrease in the economic burden was thought to have been the result of 
decrease in the length of stay in hospital.8 A retrospective study carried out in Finland studied the 
economic costs of patients hospitalized for intestinal obstruction caused by postoperative adhesions 
in Varsinais-Suomi region during the year 1999. The total cost was 181 653 UK pounds, and it was 
estimated that for whole of Finland the figure would have been 2 077 796 pounds. This would have 
put adhesive intestinal obstruction in 30th place in most costly surgical diagnosis in Finland, roughly 
corresponding the costs of rectal cancer or gastric cancer that year.9 In 2007 in the UK, it was 
estimated that adhesion-related admissions in open lower abdominal surgery would cost the NHS 
(National Health Service) more than 900 million euros over the following 10 years, and that using a 
low cost (130€) adhesion reduction product with a 25% reduction in re-admissions would save the 
NHS up to 42 million euros over the following 10 years.10 
 
2. Methods 
 
Primo Central Index, which includes databases such as Web of Science, Scopus, JSTOR, PubMed 
and DOAJ, was used in this article. Search words that were used were “postoperative”, 
”adhesion*”, ”formation*”, ”peritone*”, and combinations of all these. Additionally, articles were 
searched using specific product names, names of different cytokines and growth factors, risk factors 
etc. combining all the previously mentioned to the search word “adhesion*”. The aim was to create 
a review of adhesion formation mechanisms and the most important possible ways to prevent them. 
 
3. Peritoneum and normal peritoneal healing 
 
The peritoneum is a thin membrane that consists of two layers; the parietal peritoneum which 
covers the abdominal wall, and the visceral peritoneum which is attached to visceral organs. These 
layers are composed of simple squamous epithelial cells called mesothelial cells, which are loosely 
attached to the basement membrane underneath them.11  The mesothelium and the basement 
membrane are supported by a thin layer of submesothelial mature connective tissue containing 
collagen and scattered elastin fibers. Beneath this there is loose connective tissue with widely 
spaced collagen fibers, and also occasional fibroblasts, mononuclear phagocytes, lymphocytes and 
adipose tissue. Small blood vessels, lymphatic vessels and nerves are also present in the zone of 
loose connective tissue.12 The basement membrane together with the underlying interstitial matrix, 
which contains the previously described connective tissues, form the extracellular matrix (ECM). 
ECM contains many different components that are important in the healing process, including 
collagen I and collagen III, fibronectin, glycoproteins, fibroblasts, macrophages and blood and 
lymphatic vessels.11 
 
 
Structure of the peritoneum.13  
 
Peritoneal injury, caused by a surgical procedure for example, results in a complicated healing 
process that includes different phases and many different cells, cytokines, growth factors and other 
molecules. It can either lead to normal or impaired peritoneal healing or adhesion formation, 
depending on multiple different processes: migration, proliferation, apoptosis and cell 
differentiation for example. Various different cells, including inflammatory cells, immune cells, 
mesothelial cells and fibroblasts, are essential to the healing process as they regulate proteolysis, 
tissue remodeling, angiogenesis, the synthesis and deposition of ECM, and recruitment of additional 
cells.14  
 
Peritoneal wound healing processes and mechanisms resemble those of dermal wound healing, but 
there are also important differences: whereas dermal wounds heal from the edges toward the 
middle, peritoneal wounds are thought to heal throughout the lesion simultaneously15. Also, 
peritoneal wounds are, in contrast to dermal wounds, exposed to the peritoneal fluid, which contains 
proteins, various different cells, cytokines and growth factors. The peritoneal cavity contains 
approximately 3-50 ml of peritoneal fluid.16  
 Normal wound healing consists of different phases, including hemostasis/inflammation phase, 
proliferation phase and remodeling phase. During the hemostasis/inflammation phase, chemokines 
and growth factors are released and a clot is formed to achieve hemostasis.17  Injury of the 
peritoneal surface triggers an exudation of a high-protein fluid that contains fibrin, histamines, 
monocytes, plasma cells, polymorphonucleocytes, macrophages, mesothelial cells and histiocytes. 
The fluid coagulates within hours and fibrous bands are formed between the injured surfaces.11 
Neutrophils appear at the injury site to cleanse debris and bacteria and are followed by 
macrophages17. These inflammatory cells release, among other growth factors and cytokines, 
interleukins 1 and 6 (IL-1, IL-6) and tumor necrosis factor-alpha (TNF-alpha)18. Normally, 
fibrinolysis within 72 hours inhibits the formation of adhesions. However, if fibrinolysis is 
somehow ineffective, fibroblasts migrate into the fibrinous mass and deposit extracellular matrix, 
including collagen and fibronectin, which leads to adhesion formation.11 Fibrin degradation is 
regulated by the plasminogen system. Plasminogen activators (PAs) convert inactive plasminogen 
into active plasmin, and the process is inhibited by plasminogen activator inhibitors (PAIs).16  
 
The following phase, proliferation, includes many different cells, cytokines and growth factors, and 
lasts for days/weeks. The last phase, remodeling, can last for months or years. New cells are being 
produced, old cells are destroyed by apoptosis, and type III collagen is formed to type I collagen.17  
 
Macrophages have an important role in adhesion formation as they are present at the injury site 
throughout the whole healing interval19. They express enormous plasticity and can modify their 
functional properties depending on the environment. Increasing the number of peritoneal 
macrophages reduces adhesion formation20. Several studies suggest that macrophages have 
different functional phenotypes depending on the stage of the wound repair progress21. 
Macrophages can acquire a ‘classically activated’ phenotype (M1 type), in which case they have 
pro-inflammatory properties, or an ‘alternatively activated’ phenotype (M2 type), which is 
described as reparative/growth promoting type21 22. An important difference between these types is 
found in their arginine metabolism: M1 type macrophages metabolize arginine primarily to 
NO/citrulline, whereas M2 type macrophages metabolize arginine mostly to ornithine/urea23. M1 
type macrophages produce many different mediators and cytokines, including IL-1, IL-6, IL-12, 
TNF-alpha and inducible nitric oxide synthase. They have been shown to be common during the 
early stages of wound healing. M2 type macrophages produce both anti-inflammatory mediators 
such as IL-1 receptor antagonist and IL-10, and growth factors such as TGF-beta, VEGF and IGF-1. 
These M2 type macrophages appear to be more common during the later stages of wound repair.21 
However, it seems that these two types more or less represent the extremes of various different 
phenotypes, and that hybrid-phenotype macrophages, which have characteristics typical to both 
types, also exist21 22 24. Edwards & Mosser (2008) have suggested a different classification based on 
three different functional properties of macrophages: host defense, wound healing and immune 
regulation. This model is more like a continuous spectrum where host defense macrophages 
represent the classically activated (M1) macrophages and the other two groups consist of different 
types of alternatively activated (M2) macrophages. This classification illustrates that macrophages 
can evolve to simultaneously express characteristics that are typical to different types, and that the 
division in two groups M1 and M2 is somewhat problematic.24  
 
4. Inflammatory aspects contributing to adhesion formation 
 
Peritoneal wound healing is a complex process that includes multiple phases, various different cells 
and a vast number of growth factors and cytokines. All of these parts must be optimal for wound 
healing to occur normally. If any of the factors are inhibited or over-expressed, or if any other 
processes that affect wound healing are interrupted, this can either result in poor healing or in 
adhesion formation. 
 
 4.1 Inflammatory cytokines 
 
4.1.1 TNF-alpha 
 
Tumor necrosis factor-alpha (TNF-alpha) is an inflammatory cytokine that stimulates 
the acute-phase reaction which leads to inflammation. It is expressed in both normal and 
adhesion peritoneal fibroblasts, but compared to normal fibroblasts, adhesion fibroblasts 
have an increased quantity of TNF-alpha mRNA.11 25 Peritoneal exudate samples 
contain higher levels of TNF-alpha when gathered from rats with more severe 
adhesions.26  
 
4.1.2 IL-6 
 
Interleukin-6 (IL-6) is also an acute-phase inflammatory cytokine. IL-6 has several 
different functions, such as acting as a growth and differentiation factor or stimulating 
the expression of another genes. It acts as a marker of tissue damage of early phase. IL-6 
is stimulated by TNF-alpha and also by IL-1 and released by macrophages during 
peritoneal injury.11  Similarly to TNF-alpha, IL-6 mRNA levels are also increased in 
hypoxia and these levels are higher in adhesion fibroblasts compared to normal 
fibroblasts. 
 
4.1.3 TGF-beta1 
 
Transforming growth factor beta-1 (TGF-beta1) controls cellular proliferation, 
differentiation, apoptosis, tissue morphogenesis and wound healing. Its levels are 
increased in response to peritoneal healing. TGF-beta1 has both inactive and active 
form, of which the active form stimulates extracellular matrix (ECM) deposition and 
leads to adhesion development. TGF-beta1 may have an effect on adhesion formation by 
inducing migration of peritoneal fibroblasts as it has a potent effect on macrophage and 
fibroblast activity during wound healing. Increased levels of TGF-beta1 in hypoxia lead 
to increased PAI-1 (plasminogen activator inhibitor-1) and uPA (urokinase type 
plasminogen activator) mRNA expression which in turn leads to enhancement of anti-
proteolysis.11  
 
What these inflammatory cytokines all have in common with each other is that their levels are 
increased when adhesions are present and also in hypoxic conditions. They play an important role 
in adhesion formation as they are involved in regulating coagulation and fibrin formation25 and 
inhibition of inflammation is thought to be one of the possible ways to prevent postoperative 
adhesion formation. 
 
Levels of transforming growth factor beta-1 (TGF-beta1), interleukin 17 (IL-17) and interferon 
gamma (IFN-gamma) measured from actual patients show that, postoperatively, there are two peak 
concentrations for TGF-beta1 (12 hours and 6 days), whereas both IL-17 and IFN-gamma reach 
their peak concentrations in 1-2 days and drop to basal levels in 3-4 days after surgery. Similar 
results occur also in mice, but within shorter time periods. The first peak apparently results from 
hemorrhage early after surgery, when TGF-beta1 is released by blood platelets. During the second 
peak, TGF-beta1 is released mainly by fibroblasts. In a study by Wang et al., by neutralizing TGF-
beta1 at the second peak concentration time by injecting mice with antibodies, it was possible to 
reduce adhesion formation, while neutralization during the first peak did not have similar results, 
indicating that only the second peak point affects adhesion formation. Neutralizing IL-17 and IFN-
gamma also reduced adhesions significantly, which indicates that both these cytokines may serve as 
promoters during adhesion formation. IL-17 seems to be secreted by (gamma-delta) T cells whereas 
IFN-gamma is secreted mainly by Th1 cells.27 
 
4.2 VEGF 
 
Vascular endothelial growth factor (VEGF) is a factor that has a remarkable effect on 
angiogenesis21, which is essential to wound healing and also adhesion formation. 
VEGF stimulates endothelial cell proliferation, mediates nitric oxide synthase activity 
in endothelial cells and therefor induces new blood vessel growth in the wounded 
area28. VEGF-A plays a direct role in adhesion development29. It is secreted from 
various different cells, including platelets. Apparently, mast cells seem to have a role 
in releasing VEGF to the peritoneal cavity after operation30 . VEGF production is also 
stimulated by lactate in macrophages and lactate accumulation might have a 
significant role in adhesion formation11.  
 
4.3 Plasminogen activators 
 
Plasminogen activators (PAs) are serine proteases that are secreted by many different 
cell types and that convert plasminogen to plasmin. Plasmin is an important enzyme 
that acts, among other things, as a dissolver of blood clots. Two types of PAs have 
been identified in mammals: tissue type PA (tPA) and urokinase type PA (uPA), 
which are both inhibited by plasminogen activator inhibitor-1 (PAI-1). Reduced 
plasminogen activator activity (PAA) results in adhesion formation, whereas in cases 
where PAA Is not reduced, the fibrinous mass is degraded before fibroblast ingrowth, 
resulting in healing without adhesion formation. Regulation of PAA resides in both 
mesothelial cells and in underlying fibroblasts as well. In fibroblasts, the expression of 
tPA is reduced and PAI-1 levels are increased under hypoxic conditions, both 
resulting in reduced PAA.31  
 
4 Patient-related risks 
 
It is not completely clear whether gender affects adhesion formation rate or not. There are studies 
that suggest the frequency of adhesions is higher in females, while other studies have found them to 
be more frequent in males. Similarly, there is no real consensus on how aging affects adhesion 
formation.32 
 
Obesity (BMI greater than 30 kg/m2) affects wound healing in many ways. It is associated with 
different kinds of wound complications, reduced oxygen delivery to the wound, impaired immune 
response, and impaired fibrinolysis, which is the result of both environmental and genetic factors; 
PAI-1 levels are higher in obese individuals. Apparently, PAI-1 levels can, however, be decreased 
by long-term moderate exercise, resulting in improved fibrinolytic activity. Other factors that 
improve fibrinolytic capacity are for example a low-saturated-fat diet, coffee consumption, avoiding 
heavy alcohol consumption and avoiding smoking.32 
 
Keloids are a type of excessive wound healing. Their prevalence varies among different ethnicities 
and especially dark-skinned individuals are more likely to develop excessive scarring and keloids. 
Keloid scar contains disorganized type I collagen and type III collagen and also more elastin 
content than normal skin.17 A prospective cohort study by Stocker et al. discovered that women 
who had more than one abdominal scar, a palpable scar and/or a longer scar were most likely to 
have pelvic adhesions, meaning that skin scar characteristics are associated with the degree of 
pelvic adhesions33.  
 
Genetics have an important effect on adhesion formation risks. For example, a single nucleotide 
deletion in PAI-1 promoter causes activated PAI-1 transcription in individuals that are homozygotic 
for this deletion allele. PAI-1 transcription leads to increased plasma PAI-1 activity and decreased 
fibrinolytic activity.34 35  Another example is the IL-1RN gene, which encodes the proinflammatory 
cytokine IL-1RN (IL-1 receptor antagonist). A polymorphism of this gene has been identified and 
mutant allele (IL-1RN*2) carriers seem to have an increased risk of adhesion development.36  The 
fibrinogen gene locus has also been shown to have several polymorphisms, which affect the 
fibrinogen levels and thereby have an impact on fibrinolytic activity, although it seems that 
environmental factors (smoking, diabetes) have a greater influence on plasma fibrinogen levels than 
genetics37. 
 
It has been suggested that in the future it could become a standard to screen special factors prior to 
surgery to identify individuals that have a larger risk of adhesion formation38. These factors include 
biomarkers, genes, proteins and cytokines. This kind of screening could enable a personalized 
adhesion-prevention treatment individually for each patient. 
 
5 Surgery techniques and principles 
 
There are some guidelines and principles that should be kept in mind when performing a surgery. 
Dr. William Halsted was one of the first surgeons to promote “safe surgery”, and the so-called 
Halstedian principles include asepsis, careful handling of tissues, avoiding tension to the tissues, 
adequate hemostasis, preservation of blood supply, and obliteration of dead space39. Peritoneal 
damage should be avoided by these principles to prevent adhesion formation. Minimizing tissue 
dehydration and avoiding use of foreign bodies and unnecessary suturing or clamping is also 
recommended.40  
 
Obviously, peritonitis is always an unfortunate event for the patient. On top of increased mortality 
and other severe complications, fibrinolytic activity is also reduced in peritonitis, leading to 
increased adhesion formation. PAI-1, PAI-2, uPA, and tPA/PAI complex levels are significantly 
higher in peritonitis whereas tPA levels are significantly lower, resulting in reduced plasminogen 
activator activity, which leads to increased adhesion formation41. Bile spillage and gallbladder stone 
spillage are also related to a significant increase in adhesion formation42. 
 
Razmaria et al. examined differences in postoperative peritoneal adhesion formation between open 
ileocystoplasty and robot-assisted laparoscopic ileocystoplasty (RALI)43. The study was done on 20 
female farm-pigs which were divided into two groups. The pigs were killed on postoperative day 42 
and adhesions were visualized and classified by type and tenacity. The results showed that RALI 
achieved similar functional outcomes (return of bowel function, final weight, bladder capacity etc.) 
as the open approach. The total mean operating time was longer in the RALI arm, but the pigs in the 
RALI arm developed significantly less adhesions than those in the open arm. 
 
The incidence of adhesive small bowel obstruction was studied in a review by ten Broek et al. and it 
seemed that it was significantly lower in laparoscopic cohorts (1.4%) than in open surgery cohorts 
(3.8%). The same review also revealed that in the 10 studies that directly compared laparoscopic 
and open surgery, the incidence of adhesive small bowel obstruction was lower after laparoscopic 
surgery (odds ratio 0.38, 95% confidence interval 0.16 to 0.91).1 
 
However, the pneumoperitoneum, induced either by CO2 or helium, which is essential for 
laparoscopic surgery, creates hypoxia in the tissues which increases adhesion formation. Hypoxia 
results in a significant increase in TGF-beta1 expression in human macrophages and also in a 
significant increase in TGF-beta1, VEGF and type I collagen mRNA and protein levels in 
peritoneal fibroblasts44. Hypoxia also reduces the expression of tPA and increases levels of PAI-1, 
which both lead to reduced plasminogen activator activity and therefor also to an increase in 
adhesion formation. Hypoxia during surgery can be minimized by keeping the duration of 
pneumoperitoneum as short as possible and also by adding oxygen45. 
 
In the 1990s Luijendijk et al. studied the prevalence of foreign body granulomas in intra-abdominal 
adhesions in patients with a prior abdominal surgery. They discovered that suture granulomas were 
present in a large percentage of recent adhesions. Intra-abdominal presence of foreign material is a 
significant cause of adhesion formation and therefore intra-abdominal contamination with foreign 
material should be minimized.46  
 
Starch-powdered gloves have been shown to produce adhesions in the peritoneum47 and they should 
thus be avoided when performing intraperitoneal surgery. Tanaka et al. were able to form severe 
adhesions in mice by injecting a talc suspension intraperitoneally. As many of the adhesion-related 
studies on animals include a laparotomy to induce adhesions in animals, this could be used in the 
future as an alternative way to form adhesions.48 
 
6 Classification of adhesions 
 
There are several ways to classify and score peritoneal adhesions and no official universal 
classification system exists. It is quite common to use a classification based on the macroscopic 
appearance and consistency of adhesions. In this sort of classification the different kinds of 
adhesion types are often described verbally and then scored depending on their appearance. Lower 
points are often given to thin, filmy adhesions that are easily torn and higher points are given to 
thicker adhesions that are harder to brake, and that may even have vascularization or nerves. 
 
Adhesions can also be classified and scored depending on their length, quantity, and site. 
 
In some cases, a microscopic evaluation is also used. Samples are taken from the adhesions, 
examined through a microscope and then scored based on the cells and tissues present in the 
sample. For example, in an experimental model by Arslan et al., loose connective tissue with fine 
reticulin fibers had a score of 1 point, whereas old firm granulation tissue with hardly 
distinguishable serosal layers scored 4 points49. 
 
In an article published in 2013 Coccolini et al. proposed a standardized classification system, the 
peritoneal adhesion index PAI (not to be confused with plasminogen activator inhibitor PAI-1 
discussed previously). This system would take into account both the macroscopic appearance of the 
adhesions and their diffusion to different regions of the abdomen, and the adhesions would then be 
scored from 0 to 30 depending on these criteria.50  
 
 
Adhesions seen in a laparoscopic surgery.51  
 
7 Adhesion prevention products currently available / in research 
 
Adhesion prevention techniques are mainly divided into two categories: 1) products that act as a 
physical barrier between the tissue surfaces, hence inhibiting the forming of fibrous bands during 
the healing process, and 2) immunomodulatory products that somehow affect the healing process 
itself. 
 
8.1 Mechanical barriers (membranes, gels, solutions) 
 
Barrier products’ main idea is to cover the traumatized tissue surfaces so that they 
cannot get into contact with each other and form adhesions. There are different forms 
of barrier products, such as liquids, gels and solid membranes. 
 
8.1.1 Membranes 
 
Hellebrekers et al. evaluated, in rats, the efficacy of five different barrier materials, 
including Ringer’s lactate, PRECLUDE Peritoneal Membrane, Polyactive, Seprafilm 
and Tissucol52. Of these, only Seprafilm and PRECLUDE reduced adhesions 
significantly. PRECLUDE is a thin, non-absorbable, antithrombotic and non-reactive 
membrane. Seprafilm is a bioresorbable membrane made of hyaluronic acid and 
carboxymethyl cellulose that turns into gel within 24 hours of application and is 
cleared from the body in 28 days.  
 
Seprafilm’s efficacy was studied in patients with ulcerative colitis or familial 
polyposis in a randomized, controlled, blinded, prospective study. The patients went 
through a restorative proctocolectomy and ileal J-pouch anastomosis with diverting 
ileostomy followed by second-stage laparoscopy for ileostomy closure. 91 patients 
were treated with Seprafilm averaging 407 cm2 per patient and 92 patients were in the 
control group. Seprafilm significantly reduced the incidence, extent and severity of 
postoperative adhesions.53 
 
Interceed is a woven sheet made of oxidized regenerated cellulose that has been 
proven to reduce postoperative adhesions54 55 56. A prospective, randomized, 
controlled study by Naito et al. showed that Interceed is safe and also easy to use in 
laparoscopic colorectal surgery57. 
 A systematic review by ten Broek et al. evaluated that both hyaluronate 
carboxymethylcellulose (Seprafilm) and oxidized regenerated cellulose (Interceed) 
can safely reduce clinically relevant consequences of adhesions58. 
 
In a comparison by Gruber-Blum et al., Prevadh (oxidized bovine atelocollagen, 
polyethyleneglycol and glycerol) and Seprafilm effectively reduced postoperative 
adhesion formation in intraperitoneal mesh hernia repair surgery compared to the 
control group, while the use of SurgiWrap (polylactic acid) was associated with severe 
adhesion formation59. However, there are also results that indicate that polylactic acid 
(SurgiWrap) is effective in adhesion prevention60 61. 
 
A biodegradable composite gauze (N, O-carboxymethyl chitosan/oxidized regenerated 
cellulose (N, O-CS/ORC) composite gauze) seems to effectively prevent adhesions in 
an animal model and, in addition, it seems to both have antimicrobial function against 
E. coli and S. aureus and also have hemostatic effects62. 
 
Another possible agent to prevent intraperitoneal adhesion formation could be a 
bioabsorbable polymer film based on polyethylene glycol (PEG) and poly(D,L-
lactide) (PLA). PLA-PEG-PLA film’s efficacy seems to be equivalent in comparison 
to Seprafilm’s and Hyalobarrier’s efficacy in adhesion prevention in rats on 12th 
postoperative day, with a significant difference to the control group63. Apparently, it 
could be easier to use as it does not appear to adhere to gloves and could be easier to 
reposition in case of incorrect placement. However, clinical trials to confirm its 
efficacy are still needed. 
 
8.1.2 Liquids 
 
For vast or geometrically complex tissue surfaces it may be difficult to spread the 
agent evenly and to cover all the areas needed. That is why preformed solid films and 
membranes might in some cases be problematic to use and therefore liquid solutions 
and gels have also been investigated as adhesion-preventing barriers. Liquids are 
thought to create a ‘flotation’ effect inside the peritoneal cavity which would keep the 
tissue surfaces somewhat separated64. Mainly, these hydroflotation agents haven’t 
been shown to be quite as effective in preventing adhesions than other barrier products 
because of their short intraperitoneal residence before being absorbed65 66 67, but some 
studies show different results64. 
 
Adept is a solution made of 4% icodextrin that, when administered to the 
intraabdominal cavity, appears to safely and effectively reduce postoperative 
adhesions compared to a control group and Ringer’s lactate group68 69. It appears to 
remain in the intraperitoneal cavity for up to 96 hours in contrast to saline solution70. 
 
Hyaluronic acid has been investigated as one possible adhesion-preventing product. 
Precoating tissue surfaces with Sepracoat (0.4% hyaluronic acid) solution 
significantly reduces adhesions71, but it doesn’t seem to be effective in adhesion 
prevention if administered after lesioning72. It is unclear whether hyaluronic acid’s 
effectiveness is due to its pharmacologic activity or rather to limitation of tissue 
trauma, since its pharmacological activity may be limited because Sepracoat only 
persists at the site for approximately 24 hours71. 
 
Carboxymethylcellulose (CMC) is a polyanionic cellulose derivative and it appears its 
liquid solution is, in mice, effective in preventing adhesions when injected 
intraperitoneally48. This effect was dose-dependent. Carboxymethylcellulose sponge 
has also been found to be more effective in adhesion prevention than Interceed73. 
 
Phospholipids are polar phosphoric acid di-esters arranged as bilayer membranes that 
can act as a lubricant and a temporary coverage to serosal defects. They have a 
negatively charged choline branch chain that can bind to the positively charged 
peritoneal surface, which is why they form a membrane-like structure. In animal 
models, intra-abdominal dosage of phosphatidylcholine’s soluble form of 
approximately 70 mg/kg seems to be effective in adhesion prevention as long as the 
exposure time is at least 30 minutes, and dosage increase does not seem to enhance 
the capacity. However, doses higher than 140 mg/kg resulted in augmented 
anastomotic leakage rates and therefore caused more deaths due to peritonitis. 
Phospholipids appear to inhibit bacterial growth and intraperitoneal tumor cell 
adhesion in addition to adhesion prevention.74 
 
Liquid crystals are substances that have some of the structural characteristics of 
crystalline solids but that flow like liquids. They can be classified into two groups: 
thermotropic and lyotropic. Lyotropic liquid crystals can form lamellar and 
nonlamellar structures such as hexagonal and bicontinuous cubic phases. Liquid 
crystals could form a mechanical barrier between the tissue surfaces by generating a 
thin membrane and adhering to the tissue surface when in contact with biological 
tissues. C17 glycerin ester (G17GE) is an amphiphilic lipid of one isoprenoid-type 
hydrophobic chain. A mixture of C17GE, squalene, pluronic F127, ethanol and water 
was created and investigated as a possible adhesion-preventing agent that can form 
non-lamellar structures. Its properties could be modified by altering the lipid 
compositions, and the product would apparently be ready to use without having to mix 
ingredients during the surgery. It seems to be effective in preventing intraperitoneal 
adhesions compared to the control group and even compared to the Seprafilm-treated 
group in a rat model75. In fact, interestingly, in this particular study there was no 
significant difference between the control group and the Seprafilm-treated group. 
 
8.1.3 Gels 
 
Hydrogels have been investigated as one possible product to be used to separate the 
tissues from each other. These hydrogels include curdlan (CUR) which is a 
polysaccharide composed entirely of (1,3)-beta-D-glucose, and gellan gum (GLG), 
which is a linear anionic heteropolysaccharide composed of tetrasaccharide repeating 
units of glucose-glucuronic acid-glucose-rhamnose, containing one carboxyl side 
group76. Both of these hydrogels appear to prevent adhesion formation compared to a 
control group, but as they have different affecting mechanisms, it seems that a mixture 
of these two is even more effective than either of the two alone76. 
 
Intergel is a 0.5% ferric hyaluronate (FeHA) gel that reduces postoperative adhesions 
significantly in comparison to patients treated with Ringer’s lactate solution. Adhesion 
extent and severity were also significantly reduced and Intergel was considered as a 
safe adhesion prevention product in a randomized multicenter study by Johns et al. in 
2001.77 However, Intergel was withdrawn from the US market in 2003 because of 
possible adverse reactions, including pelvic pain, allergic reactions and increased risk 
of peritonitis78 79. 
 
Sakai et al. investigated, in mice, a possibility to form a hyaluronic acid-based 
hydrogel in situ using a cascade enzyme reaction by contact with body fluid80, which 
appeared to be effective. This method could be problematic because of the time 
needed during an operation for the hydrogel to form in situ, but by altering the 
concentration of the ingredients it was possible in this study to obtain a gelation time 
of no more than 5 seconds. 
 
8.2 Immunomodulatory products 
 
Besides mechanically inhibiting tissue surfaces from getting in contact with each other 
by barrier products, another method in adhesion prevention is immunomodulation. 
This includes products that can somehow affect the biochemistry behind adhesion 
formation. Immunomodulatory products can, for example, prevent/reduce 
inflammation, activate fibrinolysis, inhibit angiogenesis or prevent collagen synthesis. 
Many of the possible adhesion-preventing immunomodulatory products have 
multifunctional effects and they can take part in several of the previously mentioned 
immunological events. There are also specifically targeted pharmacological agents 
that aim to affect individual growth factors, proteins or cytokines, for example. Some 
of these immunomodulatory products have been investigated as fluids or solutions that 
are administered intraperitoneally so that they could have a local effect, and some 
have been studied as systemic products either administered intravenously or perorally 
before, during or after the surgery.  
 
8.2.1 Anti-inflammation 
 
Autologous intraperitoneal fat grafting has been studied on rats and results are 
promising: fat grafting significantly reduced adhesions as well as fibrosis and 
inflammation. In the study by Cil & Aydogdu, the autologous fat was harvested from 
rats’ inguinal fat pads, chopped and then transferred between cecum and abdominal 
wall through a needle.81 A recent study on mice by Laukka et al. also suggests that 
preperitoneal, instead of intraperitoneal, fat grafting by injection reduces peritoneal 
adhesion formation both in moderate and extensive adhesion models. The authors also 
observed that fat grafting increased expression of anti-inflammatory cytokine IL-10 in 
the extensive adhesions group that received a fat graft in comparison to the non-
operated control group. Faster mesothelial healing in the peritoneum was observed 
promoted by fat grafting. Fat grafting seems to have both anti-inflammatory and anti-
fibrotic effects.82  
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used mainly for pain 
relieving purposes. They inhibit cyclooxygenase-1 (COX-1) and/or cyclooxygenase-2 
(COX-2) isoenzymes. As these cyclooxygenases catalyze the formation of 
prostaglandins, which are involved in inflammation, inhibiting them also decreases 
inflammation. NSAIDs have been investigated as a possible adhesion-preventing 
substance: meloxicam and dexketoprofen seem to not have a significant effect on 
macroscopic adhesions83, but ketorolac tromethamine did significantly prevent 
adhesions in a mouse model84. 
 
In a study by Wasserberg et al. the effect of immunosuppression on postsurgical 
adhesion formation was examined. Rats received a small bowel intestinal 
transplantation and either tacrolimus as an immunosuppressive medication or no 
immunosuppression at all. Immunosuppression significantly reduced adhesion 
formation after intestinal transplantation.85 Another study by Maciver et al. showed 
that combining an immunosuppressive drug sirolimus and hydrogel and impregnating 
them on a prosthetic polypropylene mesh that was implanted operatively into the 
peritoneal cavity of mice significantly reduced postoperative adhesion formation in 
comparison to plain mesh86. 
 
In a randomized controlled trial on mice, interleukin-10 and interleukin-4 (IL-10, IL-
4) which are macrophage down-regulating cytokines, and ketorolac tromethamine 
(non-steroidal anti-inflammatory drug) were evaluated as possible adhesion-
preventing products. Both IL-10 and ketorolac separately as well as the two combined 
significantly inhibited adhesion formation, but IL-4 did not have a significant effect. 
The authors suggested there to be multiple ways by which the IL-10 could reduce 
adhesion formation: inhibiting profibrotic cytokine (such as IL-2, TGF-beta and 
platelet-derived growth factor-B) production and acting on monocytes and 
macrophages to suppress the synthesis of IL-1 and IL-6. Although IL-4 did not seem 
to prevent adhesion formation in this study, this lack of significance could be due to 
limited group size, since IL-4 has been demonstrated to inhibit TNF-alpha and IL-1 
production, which are both adhesiogenic cytokines.84  
 
Betaglucan is a glucose polymer that binds to the receptors on monocytes and 
neutrophils. It is a potent macrophage stimulator and it induces production of TNF-
alpha and interleukin-1. Although increased TNF-alpha level is in several studies 
associated with increased adhesion development, Bedirli et al. suggest that the role of 
TNF-alpha in adhesion formation is not clear. Betaglucan significantly decreased 
adhesion formation in in their study on rats after ileocolic anastomosis in the setting of 
peritonitis.87  
 
Nigella sativa is a plant that grows in countries bordering the Mediterranean Sea, 
Pakistan, India, and Turkey. Its seeds contain a lot of oil, which apparently could be 
effectively used to prevent adhesions when applied onto the surgical surface88. N. 
sativa extract suppresses secretion of IL-6, TNF-alpha and NO, which are all pro-
inflammatory mediators.89 This suggests that N. sativa’s anti-inflammatory properties 
could be the reason why it is effective against adhesions. 
 
Honey is a common household product that has been used in wound healing for ages. 
It is known to have antioxidant and anti-inflammatory effects. Honey solution sprayed 
onto the surgical zone seems to decrease adhesion formation in rats and have a 
significant effect on many adhesion-related factors such as TNF-alpha, IL-6, IL-1-
beta, TGF-beta-1, VEGF, NO, GSH, MDA compared to both control group and 
dextrose-treated group90. 
 
8.2.2 Fibrinolysis activating 
 
Statins have fibrinolytic activity and intraperitoneally administered lovastatin seems to 
prevent postoperative adhesions as effectively as Seprafilm49. 
 
Interferon gamma (IFN-gamma), which is produced, among other cells, by natural 
killer T cells (NKT cells), seems to have a crucial role in adhesion development. In an 
experimental mouse model, NKT cell-deficient mice developed adhesions poorly, but 
developed severe adhesions when after reconstitution with NKT cells from wild-type 
mice. The study also revealed that IFN-gamma might be in part responsible for 
regulation of PAI-1 and tPA.91  
 
8.2.3 Angiogenesis preventing 
 
Bevacizumab is recombinant humanized monoclonal IgG1 antibody that binds to and 
inhibits the biological activity of human VEGF thereby inhibiting angiogenesis. It has 
been shown to inhibit tumor angiogenesis in patients with advanced colorectal 
cancer.92  Ignjatovic et al. researched bevacizumab’s effects on adhesion formation in 
a study performed on 42 male Wistar rats93. All of the rats were operated on and 
adhesion formation was induced. The rats were divided into two groups: Group A 
were given NaCl intra-abdominally through a catheter after the surgery whereas 
Group B received 2.5 mg/kg bevacizumab in a similar way. The rats were killed four 
weeks after the surgery and the adhesions formed were scored both macroscopically 
and histologically. The results showed that 97.4% of the animals had formed 
adhesions. However, the severity of the adhesions was significantly lower in the group 
that received bevacizumab. This shows that a single dose of bevacizumab given 
during a surgery seems to hinder the development of abdominal adhesions. 
 
Propolis is a natural, complex product that is obtained by honey bees from different 
plants and that has many pharmacological and biological properties94. Askari et al. 
discovered that, in rats, oral gavage of propolis solution for 14 postoperative days 
significantly reduced adhesion formation (macroscopically evaluated), decreased 
levels of inflammatory cytokines (TNF-alpha, IL1-beta and IL-6), reduced levels of 
fibrosis and angiogenesis biomarkers (TGF-beta1 and VEGF) and had a significant 
effect on oxidative biomarkers (NO, MDA and GSH), and all of the effects were dose-
dependent95. 
 
In an experimental model on rats, vitamin C and vitamin E administered 
intraperitoneally during the surgery effectively prevented adhesion formation. Fibrosis 
and angiogenesis scores as well as MDA and VEGF immunoreactivity were found to 
be significantly lower in these vitamin-treated groups compared to non-treated 
group.96  
 
8.2.4 Collagen synthesis preventing 
 
Foreign bodies are often related to adhesion formation.46 Adhesion prevention to two 
commercially available polypropylene meshes (polypropylene mesh and titanium-
coated polypropylene mesh) using combined icodextrin 4% and dimetindene maleate 
was evaluated in a study by Bouliaris et al97. Icodextrin is an iso-osmolar 
biodegradable glucose polymer solution initially used for peritoneal dialysis, and it is 
thought to make a hydroflotation effect in the peritoneal cavity, creating a temporary 
physical separation of the tissue surfaces, therefore acting as a barrier. Dimetindene 
maleate is a potent H1-receptor antagonist of histamine. Histamine is released by mast 
cells after peritoneal injury or inflammation. The study was done on rabbits, and while 
icodextrin solution was instilled intraperitoneally during the surgery, dimetindene 
maleate was infused intravenously before the surgery and also intramuscularly once a 
day for 6 days following the operation. Results showed that there were significantly 
less adhesions in treated groups. Hydroxyproline, which is a component of collagen, 
levels were also measured and it was found that its level was significantly lower in 
treated groups.97 
 
8 Discussion 
 
Adhesion formation is a significant and frequent postoperative complication that causes several 
different problems including abdominal and pelvic pain, bowel obstruction, infertility and 
difficulties at reoperation. The costs of these adhesion-related problems to the society and 
healthcare system are also considerable. Adhesions are formed when normal peritoneal healing is 
somehow impaired. Normal peritoneal wound healing resembles that of dermal wounds, but there 
are also important differences, such as the presence of peritoneal fluid which contains several 
different cytokines, growth factors, cells and proteins. The peritoneal healing is a complicated 
process that includes various different cells, proteins etc. There are multiple stages and pathways 
that need to be completed for normal healing to occur. If these pathways are somehow interrupted, 
it can lead to poor healing or adhesion formation instead of normal healing. It is known that 
adhesions can be decreased using careful surgery techniques, and laparoscopic operations seem to 
cause less adhesions than open surgeries. Surgeons should be aware of the techniques that increase 
the risk of adhesion development. There are also some risk factors that are related to the patient, and 
in the future, some of them could possibly be taken into account when planning an individual 
adhesion prevention. 
Different prevention techniques and preventive products have been studied and partly the results are 
promising, but the optimal adhesion-prevention product does not yet exist. The optimal product 
should be effective in preventing adhesions, be safe to use and have minimal side effects, be easy 
for surgeons to use in laparoscopic operations as well, and have a reasonably low price. Adhesion-
preventing products can mainly be divided into two groups based on the preventive mechanism: 1) 
barrier products including solid membranes, solutions and gels that are thought to physically 
separate the damaged tissue surfaces from one another, and 2) immunomodulatory products and 
pharmacological agents that affect the biochemistry of adhesion formation processes, including 
locally and systemically (intravenously, perorally) administered products. Immunomodulatory 
products can be either specifically targeted pharmacological agents or multifunctional substances 
that have an impact on more than one part of the immunological pathways.  
Today, barrier products are more widely used, but immunomodulation seems to have interestingly 
promising results. In the future, adhesion prevention could possibly be designed more individually 
and immunomodulatory products might be one way to achieve this. Since inflammation is strongly 
related to adhesion formation98, anti-inflammatory products appear as an appealing option in the 
future of adhesion prevention. Inflammation/hemostasis is the first stage of wound healing99 and it 
is a crucial phase when it comes to adhesion formation. Especially specifically targeted 
pharmacological agents seem an interesting object of development since they have a specific effect 
during the different pathways of wound healing. Targeting a certain molecule or protein, for 
instance, might cause less unwanted side effects. To prevent unfortunate adverse effects of adhesion 
prevention (poor wound healing and anastomotic leakage for example), the impacts and 
mechanisms of the products must be well known. Further research in the field of 
immunomodulation regarding adhesion prevention is thus certainly needed. 
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